546 related articles for article (PubMed ID: 12553627)
21. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
Katugampola RP; Lewis VJ; Finlay AY
Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers.
Costanzo A; Talamonti M; Botti E; Spallone G; Papoutsaki M; Chimenti S
Dermatology; 2009; 219(1):48-53. PubMed ID: 19372639
[TBL] [Abstract][Full Text] [Related]
23. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
Sobell JM; Hallas SJ
Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
[TBL] [Abstract][Full Text] [Related]
24. Treatment of generalized vitiligo with anti-TNF-α Agents.
Alghamdi KM; Khurrum H; Taieb A; Ezzedine K
J Drugs Dermatol; 2012 Apr; 11(4):534-9. PubMed ID: 22453596
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
26. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor antagonists in the therapy of psoriasis.
Mössner R; Schön MP; Reich K
Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
[TBL] [Abstract][Full Text] [Related]
28. [The role of biological drugs in the treatment of psoriasis, results from 9 randomized placebo-controlled trials].
Kemény L; Brodszky V; Kárpáti K; Gulácsi L
Orv Hetil; 2006 May; 147(21):981-90. PubMed ID: 16812973
[TBL] [Abstract][Full Text] [Related]
29. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
30. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
Krueger G; Callis K
Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
[TBL] [Abstract][Full Text] [Related]
32. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
33. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
34. New biologic therapies for psoriatic disease.
Bohjanen KA; Prawer SE
Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
[TBL] [Abstract][Full Text] [Related]
35. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
[TBL] [Abstract][Full Text] [Related]
36. Update on the mechanisms and efficacy of biological therapies for psoriasis.
Koo J; Khera P
J Dermatol Sci; 2005 May; 38(2):75-87. PubMed ID: 15862940
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases.
Trent JT; Kerdel FA
Dermatol Nurs; 2005 Apr; 17(2):97-107. PubMed ID: 15916184
[TBL] [Abstract][Full Text] [Related]
38. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
[TBL] [Abstract][Full Text] [Related]
39. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
40. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
Young MS; Horn EJ; Cather JC
Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]